{"id":"NCT02042014","sponsor":"Novartis Pharmaceuticals","briefTitle":"Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan","officialTitle":"An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01-22","primaryCompletion":"2016-10-17","completion":"2016-10-17","firstPosted":"2014-01-22","resultsPosted":"2019-06-18","lastUpdate":"2019-06-18"},"enrollment":8,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"QTI571","otherNames":[]}],"arms":[{"label":"QTI571","type":"EXPERIMENTAL"}],"summary":"To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.","primaryOutcome":{"measure":"Serious Adverse Events","timeFrame":"Approximately 2.9 years","effectByArm":[{"arm":"QTI571","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":8},"commonTop":[]}}